Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

Valentina Marchica(Royal Veterinary College), Nicola Giuliani(University of Parma)

Cancers

March 6, 2019

10.3390/cancers11030321

Cited by 35

Related Papers

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

|The Lancet Haematology|2020|553

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target

|Blood|2016|172

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

|Blood|2013|82

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

|Oncotarget|2017|30

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients

|Frontiers in Immunology|2021|20